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SUMMARY 
EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that 
cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has 
been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in 
heterodimers with wild-type EGFR. Here, we document co-expression of EGFR and EGFRvIII in 
primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner.  
We demonstrate enhancement of downstream STAT signaling triggered by EGFR-catalyzed 
phosphorylation of EGFRvIII, implicating EGFRvIII as a substrate for EGFR. Subsequent 
phosphorylation of STAT3 requires nuclear entry of EGFRvIII and formation of an EGFRvIII-STAT3 
nuclear complex.  Our findings clarify specific oncogenic signaling relationships between EGFR and 
EGFRvIII in glioblastoma. 
 
Significance 
EGFR is commonly amplified and mutated in primary glioblastoma, a highly-malignant brain tumor.  
The most commonly observed mutant variant, EGFRvIII, signals via potential autocrine and paracrine 
loops.  Our inability to fully elucidate and target this complex signaling has contributed to failed clinical 
trials in patients with few options for therapy.  We document co-expression of EGFR and EGFRvIII in 
human tumors, identify a cell intrinsic role for co-expression in vitro and in vivo, and demonstrate that 
EGFR and EGFRvIII cooperate to phosphorylate STAT proteins, promoting malignant progression.  
Our findings elucidate signaling interactions between EGFR and EGFRvIII and suggest combinatorial 
targeting of the EGFR–EGFRvIII–STAT axis as a therapeutic approach to treat EGFRvIII-mutant 
glioblastoma. 
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INTRODUCTION 
The epidermal growth factor receptor (EGFR) plays a prominent role in many tumors including 
glioblastoma, the most common primary brain tumor. Amplification and over-expression is observed 
in >50% of glioblastoma.  Half of EGFR amplified tumors in-turn harbor the EGFRvIII mutant, an 
intragenic rearrangement generated by in-frame deletion of exons 2-7 from this receptor tyrosine 
kinase (RTK), which consequently signals constitutively in the absence of ligand (Huang et al., 1997; 
Sugawa et al., 1990; Wong et al., 1992).  A number of studies noted that amplification and over-
expression of both EGFR and EGFRvIII conferred a worse prognosis in glioma patients (Heimberger 
et al., 2005; Shinojima et al., 2003), with a clinical trial suggesting vaccination against EGFRvIII as a 
promising immunotherapy (Sampson et al., 2010).  In contrast, a recent report failed to associate 
amplification of EGFR with outcome (Weller et al., 2009).  Expression of EGFRvIII in glioblastoma is 
heterogeneous and is usually observed in a subpopulation of neoplastic cells (Nishikawa et al., 2004). 
Most antibodies against EGFR and EGFRvIII cross-react, complicating efforts to examine specific co-
expression of EGFR or EGFRvIII in individual tumor cells within a glioblastoma. 
 
Does cross-talk occur between EGFR and EGFRvIII signaling? EGFRvIII induces heparin binding 
EGF (HB-EGF) in glioma cells.  A neutralizing antibody to HB-EGF blocked EGFRvIII-induced 
proliferation, raising the possibility of a EGFRvIII–HB-EGF–EGFR autocrine loop in glioblastoma 
(Inda et al., 2010; Ramnarain et al., 2006). Expression of EGFRvIII also induces secretion of 
interleukin 6 and leukemia inhibitory factor. These cytokines activate gp130, generating a paracrine 
loop that promotes activation of EGFR in neighboring cells (Inda et al., 2010). Physical interaction of 
EGFRvIII with EGFR has additionally been proposed, associated with phosphorylation of both 
EGFRvIII and EGFR (Luwor et al., 2004).  Collectively, these studies suggest paracrine interactions 
between cells expressing EGFR or EGFRvIII, as well as physical interactions between EGFRvIII and 
EGFR within individual cells, as contributors to progression in glioma.  Here, we analyze co-
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expression of EGFR and EGFRvIII in primary glioblastoma tumor cells from patients, and elucidate 
functional implications of these findings.  
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RESULTS 
Coexpression of EGFR and EGFRvIII in Human Glioblastoma. (Figure 1A and Table S1) 
demonstrate by immunohistochemistry, the expression status of EGFR and EGFRvIII across a series 
of human primary glioblastoma tissues. Among 58 tumors, 83% (48 of 58) stained for EGFR.  Of 
these, 11 (19% of the total) were positive for EGFRvIII, with all EGFRvIII positive tumors also 
expressing EGFR. Although these data require that we subtract the EGFRvIII staining from the 
EGFR/EGFRvIII costained samples (a relatively imprecise process), these data are nevertheless 
consistent with findings by others (Biernat et al., 2004), and suggest that expression of EGFRvIII 
typically occurs in glioblastoma tumors that also over-express EGFR. Representative immunostaining 
is shown (Figure S1A-F).  
 
The EGFR antibody used in (Figure 1A, Figure S1A-F, and Table S1) recognizes both full length 
EGFR and EGFRvIII.  Therefore double-immunofluorescence staining experiments were performed 
using EGFR- and EGFRvIII-specific antibodies.  We assessed co-expression of EGFR and EGFRvIII 
in individual tumor cells in glioblastoma tissue sections from 10 cases previously shown by 
immunohistochemistry to be positive for both proteins. Representative immunostaining is shown 
(Figure 1B).  Antibody specificity is shown in (Figure S1G). The majority of cells within tumors co-
expressing EGFR and EGFRvIII showed expression of a single RTK.  In each sample however, 
individual tumor cells or groups of tumor cells were detected that over-expressed both proteins, with 
EGFR and EGFRvIII co-localized in tumor cells (Figure 1C). These results indicate that EGFR and 
EGFRvIII are jointly over-expressed within subsets of tumor cells in human primary glioblastoma 
tissue. 
 
EGFR and EGFRvIII Cooperate to Promote Tumor Growth in vitro and in vivo.  Both EGFR and 
EGFRvIII amplicons are rapidly lost upon culturing primary glioblastoma tumors (Pandita et al., 2004).  
To recapitulate co-expression, we therefore transduced EGFR, EGFRvIII, or both in human glioma 
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cell lines LN-229 and U87MG.  Because endogenous EGFR is expressed at low levels in these lines, 
we also examined mouse NIH3T3 fibroblast cells, which show little to no expression of EGFR 
(Bishayee et al., 1999).  EGFR and EGFRvIII cooperated in transformation, forming both significantly 
more and larger colonies, as compared with parent, EGFR, or EGFRvIII; when expressed in LN-229 
cells in the absence of EGF (Figure 2A and B, p<0.0001 by Student’s t test–281% increase in colony 
number with LN-229:EGFR/EGFRvIII versus LN-229:parent cells; p=0.0003 by Student’s t test-234% 
increase for LN-229:EGFR/EGFRvIII versus LN-229:EGFR cells; p=0.0011 by Student’s t test-145% 
increase for LN-229:EGFR/EGFRvIII versus LN-229:EGFRvIII cells). Addition of EGF led to increased 
colony numbers in LN-229:EGFR/EGFRvIII cells (p=0.0083 by  Student’s t test–139% increase in the 
presence EGF when compared with absence of EGF) with little effect on cells expressing vector, 
EGFR, or EGFRvIII alone. LN-229:EGFR/EGFRvIII cells were transformed to modest levels without 
EGF treatment, perhaps due to EGFR ligands present in the fetal calf serum used in this assay 
(Figure 2A and B). Similar results were obtained in U87MG cells (Figure S2). Importantly, to exclude 
the possibility that increased transformation was related to doubling of total levels of EGFR/EGFRvIII 
kinase activity, we also analyzed untransformed NIH3T3 cells. In these cells (Figure S2), EGFR and 
EGFRvIII synergize in transformation, suggesting a greater than additive effect. Similar results were 
observed for LN229 cells in vivo, where EGFR and EGFRvIII led to a greater than additive effects 
(compared to LN229:EGFR or LN229:EGFRvIII cells) in driving tumor size (Figure 2C and D). 
 
To further evaluate the oncogenic potential of cells co-expressing EGFR and EGFRvIII in vivo, we 
established xenografts from cell lines in Figure 2A and B.  Growth of EGFR/EGFRvIII tumor 
xenografts was increased markedly (Figure 2C and D) as compared with tumors driven by parent, 
EGFR, or EGFRvIII (p=0.0003, Student’s t test–198% increase in LN-229:EGFR/EGFRvIII cells 
compared with LN-229:parent cells; p=0.0005, Student’s t test–82% increase when compared with 
LN-229:EGFR cells; and p= 0.0028, Student’s t test–31% increase when compared with LN-
229:EGFRvIII cells).  
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Co-expression of EGFR and EGFRvIII phosphorylates STAT proteins in vitro and in vivo.  No 
significant differences were observed in the abundance of phosphorylated AKT (p-AKT) and p-ERK 
among EGF-treated LN-229:EGFR/EGFRvIII, LN-229:EGFR, and LN-229:EGFRvIII lines (Figure 3A). 
STAT signals downstream of EGFR, is activated in 60% of glioblastoma patients, drives progression 
in animal models of glioma, and correlates inversely with survival (Birner et al., 2010; Darnell et al., 
1994; Doucette et al., 2012; Shao et al., 2003), prompting us to analyze this pathway.  Addition of 
EGF led to a statistically significant increase in the abundance of p-STAT3 and p-STAT5 in 
EGFR/EGFRvIII cells, as compared with parent, EGFR, and EGFRvIII cells (Figure 3A and Figure 
S3). Induction of p-STAT3 and p-STAT5 in cells co-expressing EGFR/EGFRvIII was also observed in 
U87MG human glioma, and mouse fibroblast NIH3T3 cells (Figure S3).  Higher levels of p-STAT3 
and p-STAT5 were also observed in xenografted tumors from LN-229:EGFR/EGFRvIII cells, as 
compared with parent, EGFR, or EGFRvIII tumors (Figure 3A). Interestingly, although levels of p-
STAT3 and p-STAT5 were very low in cultured LN-229:EGFRvIII cells, both STAT3 and STAT5 were 
phosphorylated to a moderate degree in xenografted EGFRvIII tumors (perhaps due to re-expression 
of EGFR) albeit to lower levels than observed in EGFR/EGFRvIII tumors (Figure 3A).   
 
We evaluated whether STAT signaling correlated with co-expression of EGFR and EGFRvIII in 
human tumors.  Analysis of 58 human glioblastoma tumors demonstrated that expression of EGFRvIII 
was limited to tumors that expressed EGFR (Figure 1A and Table S1). We therefore further analyzed 
primary human glioblastoma tumors negative for expression of both EGFR and EGFRvIII, positive for 
EGFR alone, or positive for both EGFR and EGFRvIII. Figure 3B demonstrates that p-STAT3 was 
expressed at highest levels in primary human tumors that co-expressed EGFR and EGFRvIII, and at 
lower levels in tumors that expressed either EGFR alone, or neither kinase. Analysis of nine 
additional human glioblastoma tumors demonstrated general alignment among levels of EGFR, 
EGFRvIII and p-STAT proteins (Figure S3E-G).  Immunohistochemical staining of 10 
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EGFR/EGFRvIII-positive primary human glioblastoma tissue sections demonstrated subsets of 
tumors cells with strong nuclear expression of p-STAT3, that overlapped regionally with both EGFR 
and EGFRvIII in every case (representative staining shown in Figure 3C); with immunofluorescence 
suggesting some nuclear or perinuclear expression of EGFRvIII (Figure S3H) and co-localization of p-
STAT3 with EGFRvIII or with EGFR within individual cells (Figure 3D).    
 
We next examined the kinetics through which EGFR and EGFRvIII could enhance STAT signaling.  
EGF treatment of LN-229:EGFR/EGFRvIII cells led to prolonged phosphorylation of both EGFR and 
EGFRvIII, starting at 15 min, continuing through 60 min; and correlating with sustained 
phosphorylation of STAT3 and STAT5 (Figure 4A).  In contrast, phosphorylation of EGFR in LN-
229:EGFR cells peaked at ~30 min, then declined more rapidly, with less robust peak and temporal 
phosphorylation of STAT signaling.  In LN-229:parent and LN-229:EGFRvIII cells, EGF treatment had 
little effect on phosphorylation of EGFRvIII, STAT3, or STAT5. Using the protein synthesis inhibitor 
cycloheximide, we showed similar half lives for EGFR, EGFRvIII, and STAT3 proteins in LN-
229:EGFR/EGFRvIII cells, as compared with parent, EGFR, and EGFRvIII cells (Figure 4B), 
indicating that prolonged temporal phosphorylation of STAT3 in LN-229:EGFR/EGFRvIII cells was 
independent of receptors and STAT3 stability. These data suggest that EGFR and EGFRvIII 
coordinately drive enhanced and prolonged STAT phosphorylation.  
 
To address biological effects of EGFRvIII-STAT signaling in human tumors, we queried TCGA data 
for key expression differences in EGFR/EGFRvIII co-amplified tumors, comparing these to tumors 
with amplification of EGFR in the absence of EGFRvIII.  These data (Figure S4), demonstrate 33 
genes that were differentially expressed between the EGFR-EGFRVIII and EGFR-amplified samples. 
Of note, these genes converge on PKC and PLC, both of which have been previously demonstrated 
to interact with STAT3(Lo et al., 2010; McBeth et al., 2013; Parsons et al., 2013) 
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EGFR Phosphorylates vIII, Cooperating in Transformation.  Surprisingly, the abundance of 
phosphorylated EGFRvIII was strongly increased when LN-229:EGFR/EGFRvIII cells were treated 
with EGF (Figure 3A), evident at Y1068 and Y1173 tyrosine residues (Figure S3). EGFRvIII is unable 
to bind ligand, and demonstrates constitutive albeit low activity, whereas EGFR shows ligand-
dependent signaling.  Accordingly, EGF-induced increase in phosphorylation of EGFRvIII in LN-
229:EGFR/EGFRvIII cells suggests that EGFR cross-phosphorylates EGFRvIII in response to EGF.   
 
To explore mechanisms through which EGFR could phosphorylate EGFRvIII, we tested analogue-
sensitive (as) alleles of EGFR, engineered to accept analogs of ATP not efficiently used by wild-type 
kinases (Bishop et al., 2000; Blair et al., 2007).  NIH3T3 cells, which have low or undetectable levels 
of endogenous EGFR (Bishayee et al., 1999), were stably transduced either with wild-type or 
analogue sensitive alleles of EGFR (EGFRas3) or EGFRvIII (vIIIas3), individually and in combination. 
Cells transduced with EGFRas3 demonstrated EGF-dependent phosphorylation of EGFRas3; whereas 
cells transduced with EGFRvIIIas3 showed baseline phosphorylation of vIIIas3, suggesting retention of 
basal and EGF-driven kinase activities (Figure 5A and B). Treatment with the bulky covalent ATP-
analogue 4TB [N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)acrylamide (Blair et al., 2007)] blocked 
phosphorylation of EGFRas3, EGFRvIIIas3, and downstream targets. Under the same conditions, as 
expected, 4TB had no effect on phosphorylation of downstream signaling in cells transduced with 
either wild type EGFR or EGFRvIII. 
 
Having confirmed that EGFRas3 and EGFRvIIIas3 could be blocked by 4TB, we next analyzed 
transphosphorylation.  In EGFRas3/EGFRvIII cells, 4TB blocked phosphorylation of EGFRas3, 
EGFRvIII, and STAT3, consistent with EGFRvIII phosphorylation by EGFR (Figure 5A and B).  In 
EGFR/EGFRvIIIas3 cells in the absence of EGF, 4TB potently blocked phosphorylation of vIIIas3 (likely 
related to the low intrinsic activity of EGFRvIII), with no impact on phosphorylation of EGFR.  In the 
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absence of EGF, p-STAT3 was undetectable in these cells.  In the presence of EGF however, 4TB 
was unable to block phosphorylation of EGFR in EGFR/EGFRvIIIas3 cells with modest effects on 
phosphorylation of both EGFRvIIIas3 and p-STAT3.  Notably, in response to EGF, the abundance of p-
STAT3 in EGFR/EGFRvIIIDY5 cells [which contain five non-phosphorylatable phenylalanine residues 
in place of tyrosine in the C-terminus of EGFRvIII (Huang et al., 1997)] was much lower than that in 
EGFR/EGFRvIII cells. Consistent with EGFR/EGFRvIIIDY5 result, treatment of LN-229:EGFR/EGFRvIII 
cells with EGFRvIII siRNA (Fan and Weiss, 2004) led to decreased phosphorylation of STAT3 (Figure 
S5A-C).  
 
We used densitometry to quantify the relative levels of p-STAT3 in LN-229:EGFR/EGFRvIII and 
NIH3T3:EGFR/EGFRvIIIDY5 cells. The relative intensity of p-STAT3 in NIH3T3:EGFR/EGFRvIII cells 
(after addition of EGF, 15 min, and normalization to β-Tubulin) was set to 100%. The relative intensity 
of p-STAT3 dropped to 67% in NIH3T3:EGFR/EGFRvIIIDY5 cells (Figure 5B). Similarly, in Figure S5, 
we set the relative intensity of p-STAT3 in LN-229:EGFR/EGFRvIII cells treated with control siRNA to 
100% (after addition of EGF, 15 min and normalization to GAPDH). The relative intensity of p-STAT3 
dropped to 59% in response to EGFRvIII siRNA in Figure S5B and to 55% in Figure S5C 
respectively.  These data suggest that phosphorylation of EGFRvIII contributes to STAT activation. 
 
We next addressed functional effects of selective EGFR and EGFRvIII inhibition.  Consistent with our 
immunoblot results (Figure 5A and B), treatment of EGFRas3/EGFRvIII cells with 4TB led to decreases 
in both proliferation and focus formation, inducing arrest at G1. In contrast, 4TB had a modest effect 
on EGFR/EGFRvIII3as3 or had little effect on EGFR/EGFRvIII cells, with control EGFRas3 and 
EGFRvIIIas3 cells showing expected responses (Figure 5C). Collectively, data in Figure 5 suggest that 
EGFR phosphorylates EGFRvIII, and that EGFR and EGFRvIII converge to phosphorylate STAT 
proteins, thereby driving transformation.  
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EGFRvIII is a Substrate for EGFR.  EGFR family members signal through allosteric interactions 
between monomers, which form an asymmetric dimer. In this dimer, only one kinase is catalytically 
activated (the receiver kinase) whereas the other functions as the allosteric activator (the activator 
kinase). To determine whether EGFR and EGFRvIII signal as an asymmetric heterodimer, we 
generated receiver-impaired (I682Q) and activator-impaired (V924R) mutations in both EGFR and 
EGFRvIII (Jura et al., 2009).  LN-229 and NIH3T3 cells were stably transduced either with single or 
double retroviral constructs as shown in (Figure 6A and Figure S6). As expected, co-expression of 
EGFRI682Q and EGFRV924R restored significant signaling activity, as compared with cells transduced 
individually with either activator-impaired EGFRV924R or receiver-impaired EGFRI682Q (Figure S6).  
 
To address whether EGFR and EGFRvIII signal as a heterodimer, we next generated 
EGFRI682Q/EGFRvIIIV924R cells, in which EGFR is an obligate activator, and EGFRvIII an obligate 
receiver.  This combination (as well as the reciprocal EGFRV924R/EGFRvIIII682Q) failed to restore 
signaling. Co-immunoprecipitation results also failed to demonstrate a complex between EGFR and 
EGFRvIII (Figure S6I and J). In contrast when EGFRwt was co-transduced with EGFRvIIII682Q or 
EGFRvIIIV924R, downstream signaling from EGFRvIII was restored  (Figure 6B). Collectively, these 
data suggest that EGFR and EGFRvIII signal together through a heterodimerization–independent 
mechanism.  
 
We next asked whether EGFRvIII could serve as a substrate for EGFR.  Kinase dead alleles 
EGFRD813N and EGFRvIIID813N showed low kinase activities as compared with EGFRwt and EGFRvIIIwt 
alleles (Figure 6C and D). The EGFRvIIID813N protein was fully phosphorylated by EGFRwt, whereas 
EGFRvIIIwt was unable to phosphorylate kinase dead EGFRD813N (Figure 6C and D). These 
EGFRvIIID813N data, in conjunction with our EGFRvIIIDY5 experiments (Figure 5B), suggest EGFRvIII is 
a substrate of EGFR, with phosphorylation of both EGFR and EGFRvIII promoting increased and 
 12 
sustained levels of phosphotyrosine in the tails of these two RTKs, phosphorylating STAT proteins, 
and driving progression in glioblastoma. 
 
EGFR and EGFRvIII cooperate to phosphorylate STAT in nucleus. To address how EGFR and 
EGFRvIII converge on STAT signaling, we analyzed subcellular fractions.  In the absence of EGF, 
both EGFR and EGFRvIII were detected in membrane, cytoplasmic, and nuclear extracts in LN-
229:EGFR, LN-229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells (Figure 7A). EGF treatment of LN-
229:EGFR/EGFRvIII cells resulted in phosphorylation of EGFRvIII in both cytoplasmic and nuclear 
protein extracts (Figure 7A), associated with increased expression of EGFRvIII in the nucleus (Figure 
7A), and with sustained phosphorylation of STAT3 and STAT5 in the nucleus. In contrast, EGF 
treatment of LN-229:EGFRvIII cells had little effect on expression of nuclear EGFRvIII, 
phosphorylation of EGFRvIII, or STAT signaling. EGF treatment only transiently phosphorylated 
nuclear STAT proteins in LN-229:EGFR cells, and had little effect in LN-229:parental cells (Figure 
7A).  
 
We used densitometry to quantify the relative levels of EGFRvIII phosphorylation in each fraction in 
LN-229:EGFR/EGFRvIII cells. The relative intensity of p-EGFRvIII in membrane fractions without 
EGF stimulation was set to 100% after normalization to β-Tubulin from membrane fractions.  The 
relative intensity dropped to 86% after EGF stimulation for 15 min, and to 90% after EGF stimulation 
for 6h.  Again, we set the relative intensity of p-EGFRvIII in cytoplasm fractions without EGF 
stimulation to 100%, after normalization to β-Tubulin from cytoplasmic fractions.  The relative intensity 
then increased to 353% after EGF stimulation for 15 min, and to 340% after EGF stimulation for 6 h.  
In nuclear fractions, we again set the relative intensity of p-EGFRvIII in nuclear fractions without EGF 
to 100% after normalization to Lamin B1 from nuclear fractions.  The relative intensity increased to 
126% after EGF stimulation for 15 min, and to 142% after EGF stimulation for 6 h. These data 
 13 
suggest that EGF treatment of EGFR/EGFRvIII cells increased phosphorylation of EGFRvIII in 
cytoplasmic and nuclear fractions, but not in membrane fractions (Figure 7A). 
 
To clarify whether EGFRvIII undergoes nuclear translocation to phosphorylate STAT proteins, we 
transfected LN-229 cells with EGFRvIIIdNLS, an allele of EGFRvIII defective for nuclear entry (Lo et 
al., 2010), and established stable LN-229:EGFRvIIIdNLS and LN-229:EGFR/EGFRvIIIdNLS cell lines. 
LN-229:EGFRvIIIdNLS and LN-229:EGFR/EGFRvIIIdNLS cells expressed levels of EGFRvIII 
equivalent to those in LN-229:EGFRvIII and LN-229:EGFR/EGFRvIII cells. EGF treated LN-
229:EGFR/EGFRvIII cells had higher levels of phosphorylated STAT proteins, as compared to levels 
in LN-229:EGFR/EGFRvIIIdNLS cells (Figure 7B). Consistent with our immunoblot results using 
whole cell lysates (Figure 7B top panel) EGF treatment of LN-229:EGFR/EGFRvIIIdNLS cells 
resulted in  decreased phosphorylation of STAT in the nuclear fraction (Figure 7B bottom panel).  
These data suggest that EGF treatment of EGFR/EGFRvIII cells enhances both nuclear transport of 
EGFRvIII, and phosphorylation of STAT in the nucleus. 
 
We next asked whether nuclear EGFR and EGFRvIII could complex with STAT3 in the nucleus. 
Nuclear STAT3 was immunoprecipitated, and immunoblots analyzed to detect nuclear EGFR and 
EGFRvIII (Figure 7C).  Nuclear lysates, whole cell lysates (input) and nuclear immunoprecipitations 
are shown in (Figure 7C).  In LN-229:EGFR/EGFRvIII cells, the levels of nuclear EGFRvIII complexed 
to STAT3 were enhanced following 15 min of EGF treatment.  In contrast, EGF treatment had little 
effect on the EGFRvIII/STAT3 complex in LN-229:vIII cells. As expected, mouse IgG did not pull 
down STAT3 or EGFR/EGFRvIII. Collectively, these data suggest that EGFR phosphorylates 
EGFRvIII, leading to increased nuclear translocation of EGFRvIII, and enhanced binding of EGFRvIII 
to STAT3 in the nucleus. 
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High STAT3 activity may contribute to resistance of GBM patients to EGFR inhibitors (Mellinghoff et 
al., 2005; Reardon et al., 2006). Might inhibition of STAT3 cooperate with inhibition of EGFR in 
glioma?   To partially address this issue, we showed that cells treated with the STAT3 tool inhibitor 
Stattic in combination with the EGFR inhibitor erlotinib showed differential induction of apoptosis (Fig 
S7). Baseline levels of apoptosis differ among the four lines, consistent with EGFR and EGFRvIII 
independently modestly blocking basal apoptosis, with a more prominent effect of EGFR/EGFRvIII in 
combination.  Thus, LN-229:EGFR/EGFRvIII cells at baseline showed 2.1% apoptosis, compared to 
44.8% in response to Stattic and erlotinib (~21 fold change).  LN-229:EGFRvIII cells at baseline 
showed 3.4% apoptosis, compared to 46.9% in response to Stattic and erlotinib (~14 fold change).  
By comparison, LN-229:EGFR cells at baseline showed 4.3% apoptosis, compared to 40.6% in 
response to Stattic and erlotinib (~9 fold change); while LN-229:parent cells at baseline showed 6.8% 
apoptosis, compared to 42.1% in response to Stattic and erlotinib (~6 fold change). These data 
suggest cooperative blockde of EGFR and STAT3 as a developmental therapeutic strategy in 
EGFR/EGFRvIII coamplified glioma. 
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DISCUSSION   
Amplification and over-expression of EGFR represent striking features of primary glioblastoma, with 
frequent co-amplification of EGFR and its deletion mutant, EGFRvIII (Huang et al., 1997; Sugawa et 
al., 1990; Wong et al., 1992). Using immunofluorescence double staining with EGFR- and EGFRvIII-
specific antibodies, we demonstrate that EGFR and EGFRvIII co-localize within individual tumor cells 
in glioblastoma. We further highlight cooperation between EGFR and EGFRvIII in transformation in 
vivo, with cell-based experiments showing that EGF treatment of cells expressing both EGFR and 
EGFRvIII resulted in phosphorylation of both kinases. This result was unexpected, as EGFRvIII is 
unable to bind or be activated in response to EGF.  Using chemical genetic approaches, we found 
that EGFR promoted unidirectional EGFRvIII signaling in glioblastoma cells, driving further 
phosphorylation of STAT proteins, and enhanced malignancy. It is intriguing that enhanced STAT 
signaling is so selectively affected by EGFR/EGFRvIII cross talk, while signaling through PI3K and 
MAPK is less prominently affected. In addition, STAT signaling has been suggested to feature 
prominently in glioma stem cells (Dubuc et al., 2013).   That rare cells within GBM tumors co-amplify 
EGFR and EGFRvIII, and phosphorylate STAT3 could be consistent with a role for STAT3 activation 
within the stem cell compartment of GBM.   
 
How does EGFR activate EGFRvIII?  While others have demonstrated physical binding of these two 
kinases, our co-immunoprecipitation experiments failed to demonstrate this interaction.  We were 
similarly unable to reconstitute signaling in a heterodimeric complex where EGFR was an obligate 
allosteric activator, and EGFRvIII an obligate receiver.  Kinase dead EGFRvIII was readily 
phosphorylated by EGFR, suggesting EGFRvIII as a substrate of EGFR.  Phosphorylation of both 
EGFR and EGFRvIII were required to fully phosphorylate STAT proteins.  EGFR, when expressed 
alone, led to lower level and shorter duration of STAT phosphorylation, as compared to levels and 
duration observed in cells co-expressing both EGFR and EGFRvIII.  Further, co-expression of EGFR 
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with EGFRvIIIDY5, a mutant in which tyrosines in the tail of EGFRvIII were replaced with 
phenylalanines, blunted phosphorylation of STAT3 protein.    
 
Analysis of human glioblastoma tumors demonstrated alignment among EGFR, EGFRvIII and STAT 
signaling in tumors, supporting a model in which EGFR activation of EGFRvIII leads to 
transphosphorylation of both kinases, converging on STAT signaling. Using subcellular fractionation, 
we further demonstrated that EGFR phosphorylation of EGFRvIII led to nuclear transport of EGFRvIII, 
and enhanced the formation of a complex between EGFRvIII and STAT3 in the nucleus. These data 
suggest that EGFR and EGFRvIII coordinately drive enhanced and prolonged STAT activity in the 
nucleus. It remains possible however, that very high levels of EGFR could subserve this role even in 
the absence of EGFRvIII.    
 
In this study, we identify an EGFR-EGFRvIII-STAT signaling axis in a subset of glioblastomas that co-
amplify EGFR and EGFRvIII within individual tumor cells. Given that coexpressed EGFR and 
EGFRvIII, and high levels of STAT signaling may confer both more aggressive behavior in 
glioblastoma (Abou-Ghazal et al., 2008; Birner et al., 2010; Shinojima et al., 2003), our findings 
suggest targeting EGFR in conjunction with STAT signaling as a therapeutic strategy for patients with 
EGFRvIII-positive glioblastoma. 
 
EXPERIMENTAL PROCEDURES 
Tumor Samples 
Primary tumor samples were obtained in accordance with research ethics board approval from UCSF 
and the Heinrich Heine University.  Informed consent was obtained from all UCSF patients.  Archival 
samples from Dusseldorf were investigated in an anonymized manner, approved by the ethics 
committee of the Medical Faculty of Heinrich Heine University. 
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Construction of EGFR and EGFRvIII mutants. 
Retroviral-based pWLZ-hygro-EGFR-as3 was described previously (Blair et al., 2007). pWLZ-hygro-
EGFRas3 plasmid was digested with BstXI and ligated into a similarly digested pLRNL-neo-EGFRvIII 
plasmid, generating retroviral-based pLRNL-neo-EGFRvIII-as3, an analogue-sensitive allele of 
EGFRvIII. pLRNL-neo-EGFRvIII-DY5 (Johns et al., 2007) and pCMV-tag5A-EGFRvIIIdNLS (Lo et al., 
2010) were generously provided by Dr. Frank Furnari and Hui-Wen Lo, respectively.  Point mutations 
(I682Q and V924R) were engineered into the pWLZ-hygro-EGFR or into the pLRNL-neo-EGFRvIII by 
site-directed mutagenesis (QuickChange Mutagenesis kit, Stratagene). All primer sequences are in 
(Thiel and Carpenter, 2007).  Point mutation pcDNA-neo-EGFR (D813N) plasmid was from Natalia 
Jura, UCSF; digested with BstXI, ligated into a similarly digested vector and used to generate either 
pWLZ-hygro-EGFR (D813N) or pLRNL-neo-EGFRvIII (D813N). All mutants were sequence validated. 
 
Cell lines, reagents, transfection, and transduction. Human glioma cell lines LN-229 and U87MG 
were obtained from the Brain Tumor Research Center at UCSF. NIH3T3 mouse fibroblasts were from 
ATCC. These and derivate lines were grown in 0.5% or 10% FBS. To generate retrovirus, the 
packaging cell line 293T was co-transfected with plasmids gag/pol and VSVg, using Effectene-
transfection reagent (Qiagen). High-titer virus was collected at 48 hr and used to infect cells as 
previously described(Fan et al., 2007). pCMV-tag5A-EGFRvIIIdNLS plasmid was generously 
provided by Dr. Hui-Wen Lo, Duke University, and transfected into LN229:parent or LN229:EGFR 
cells. Transfected and transduced cells were selected as pools with G418 (800 g/ml) or hygromycin 
(500 g/ml) for 2 weeks. EGF was from (Roche). Cyclohexmide and Stattic were from (Sigma). 4TB 
[N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)acrylamide were synthesized as described (Blair et al., 
2007). 
 
Immunohistochemical analyses. 
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Immunohistochemical staining was performed by the UCSF Neurosurgery Tissue Core. Paraffin-
embedded sections (5 μm) of human GBM were immunostained on the Benchmark XT automated 
stainer (Ventana Medical System, Tucson, AZ). Antibodies were detected with the Ventana iVIEW 
DAB detection kit (yielding a brown reaction product). The EGFR antibody utilized in this study was a 
mouse monoclonal antibody obtained from Ventana 790-2988 (clone 3C6) which recognizes the 
extracellular domain of both full length and the EGFRvIII variant of EGFR and was supplied as part of 
an FDA validated clinical diagnostic kit for EGFR abundance, used clinically to assess EGFR status. 
The EGFRvIII mouse monoclonal antibody was from Duke University (L8A4). Slides were 
counterstained with hematoxylin. Immunostaining results were graded in a semi-quantitative manner 
by determining the intensity of staining of each section and grading from 0 (no staining), 1 (1-25% 
immunoreactivity of cells), 2 ((26-75% immunoreactivity) or 3 (>75% immunoreactivity). Human 
glioblastoma tissue samples were routinely fixed in 4% buffered formaldehyde and embedded in 
paraffin. Five m thick tissue sections were deparaffinized in xylene and rehydrated over a graded 
ethanol series. For antigen retrieval, rehydrated sections were treated in 10 mM citrate buffer at pH 
6.0 (for EGFRvIII and p-STAT3) or at pH 9.0 (for EGFR) for 20 min in a steamer. Sections were 
immunostained with antibodies against EGFR (mouse monoclonal DAK-H1-WT, Dako, diluted 1:200), 
EGFRvIII (rabbit polyclonal 6549, Celldex, diluted 1:5000), p-STAT3 (Tyr705) (rabbit monoclonal 
antibody D3A7 or mouse monoclonal antibody 3E2, Cell Signaling, each diluted 1:50). 
Immunohistochemistry was performed on the Dako Autostainer Plus automated slide processing 
system using the Ultravision LP Large Volume Detection System HRP Polymer (Thermo Scientific) 
for detection of antibody binding according to the manufacturer’s protocol. 3,3-Diaminobenzidine was 
used as substrate for the peroxidase reaction. Slides were counterstained with hemalum, dehydrated 
and mounted in DePeX (Serva) mounting medium.  
 
Double-immunofluorescence analyses. 
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Glioma cells grown as monolayer cultures on chamber slides were fixed with methanol. Formalin-
fixed paraffin sections from primary tumor tissues were deparaffinized in xylene and rehydrated over 
a graded ethanol series, followed by treatment in 10 mM citrate buffer at pH 6.0 for 20 minutes in a 
steamer for antigen retrieval. Rehydrated fixed cells and tissue sections were blocked 5 min with Ultra 
V Block (Thermo Scientific) and incubated overnight at 40C with primary antibodies against EGFR 
(mouse monoclonal DAK-H1-WT, Dako) and EGFRvIII (rabbit polyclonal 6549, Celldex) diluted 1:50. 
Additional double-labeling experiments were performed with antibodies against EGFR and p-STAT3 
(Tyr705) antibody (rabbit monoclonal antibody D3A7, Cell Signaling), or antibodies against EGFRvIII 
and p-STAT3 (Tyr705) antibody (mouse monoclonal antibody 3E2, Cell Signaling). Three washing 
steps were followed by incubation at room temperature for 1 hr with Alexa Fluor 488/594 secondary 
antibodies (Invitrogen) diluted 1:500. Following repeated washing, stained sections and cells were 
mounted in ProLong® Gold antifade reagent (Invitrogen) with 4',6-diamidino-2-phenylindole (DAPI).  
 
In Vitro and In Vivo growth assays 
We used the Cell Transformation Detection Assay kit (Millipore) to evaluate colony formation on soft 
agar. Briefly, plates were pre-coated with 0.7% agarose as the bottom layer.  Cells were seeded at a 
density of 1  104 cells per 6-well in triplicate for each cell line and cultured in 0.35% agarose as the 
top layer in DMEM (without phenol red) plus 10% FBS at 370C for 3 weeks. The cells were kept wet 
by adding a small amount of culture media.  EGF (50 ng/ml) was added every 5 days. Colonies were 
stained overnight at 370C (Cell transformation detection assay kit, Millipore). Colony numbers in the 
entire well were counted under the microscope. For nude-mice, LN-229:parent, LN-229:EGFR, LN-
229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells (106) were injected subcutaneously just caudal to 
the left forelimb in 4- to 6 week-old BALB/c nu/nu mice (Harlan Sprague-Dawley). Tumor diameters 
were measures with calipers at 7-day intervals, and volumes calculated from five mice per data point 
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(mm3= width2  Length/2). UCSF’s Institutional Animal Care and Use Committee approved all 
experiments. Each value represents mean tumor volume +/- standard error obtained from five mice.  
 
Immunoblotting Membranes were blotted with p-EGFRY845, p-EGFRY992, p-EGFRY1045, p-EGFRY1068, 
p-AKTS473, AKT, p-S6 ribosomal proteinS235/236, S6 ribosomal protein, p-ERKT202/Y204, p-STAT3 
(Tyr705), STAT3, STAT5, Lamin B1 (all from Cell Signaling), p-EGFRY1173, EGFR, ERK, normal 
mouse IgG (Santa Cruz Biotechnology), p-STAT5Y694 (BD Transduction Laboratories), GAPDH, or -
Tubulin (Upstate Biotechnology). Bound antibodies were detected with HRP-linked anti-mouse or 
anti-rabbit IgG (Calbiochem), followed by ECL (Amersham). 
 
Subcellular fractionation and Immunoprecipitation (IP) 
For multi-compartmental fractionation of cells we used the subcellular protein fractionation kit 
(Thermo Scientific Pierce) according to the manufacturer’s instructions. For immunoprecipitation, 200 
μg nuclear protein were incubated with 1 μg anti-STAT3 mouse monoclonal antibody (Cell Signaling) 
or control mouse IgG at 40C overnight with gentle agitation. Following addition of 20 μl protein G-
agarose and incubation for 1 hr at 40C, the immunocomplexes were pelleted, washed for multiple 
cycles at 40C, and then subjected to SDS-PAGE and Western blotting analysis probing for EGFR 
(rabbit antibody that recognize both EGFR and EGFRvIII, Santa Cruz Biotechnology). 
 
SUPPLEMENTAL INFORMATION 
Supplemental information includes seven figures, one table, and Supplemental Experimental 
Procedures and can be found at a single PDF file. 
 
ACKNOWLEDGMENTS  
 
Supported by K08NS079485 (W.C.G), U54CA163155 and U01CA176287 (W.A.W), Howard Hughes 
Medical Institute (K.M.S), and the Samuel Waxman Cancer Research Foundation (W.A.W., K.M.S).  
 21 
We thank Albert Baldwin, Lew Cantley, Peter Jackson, Mark Lemmon, and Frank McCormick for 
useful discussions, Miller Huang, Justin Meyerowitz and Theo Nicolaides for critical review, Frank 
Furnari for plasmid pLRNL-neo-vIII-DY5, Hui-Wen Lo for plasmid pCMV-tag5A-vIIIdNLS, and Cynthia 
Cowdrey and King Chiu for immunohistochemistry. 
 
   
  
 22 
REFERENCES  
Abou-Ghazal, M., Yang, D. S., Qiao, W., Reina-Ortiz, C., Wei, J., Kong, L. Y., Fuller, G. N., Hiraoka, 
N., Priebe, W., Sawaya, R., and Heimberger, A. B. (2008). The incidence, correlation with tumor-
infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. 
Clin Cancer Res 14, 8228-8235. 
Biernat, W., Huang, H., Yokoo, H., Kleihues, P., and Ohgaki, H. (2004). Predominant expression of 
mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14, 131-136. 
Birner, P., Toumangelova-Uzeir, K., Natchev, S., and Guentchev, M. (2010). STAT3 tyrosine 
phosphorylation influences survival in glioblastoma. Journal of neuro-oncology 100, 339-343. 
Bishayee, A., Beguinot, L., and Bishayee, S. (1999). Phosphorylation of tyrosine 992, 1068, and 1086 
is required for conformational change of the human epidermal growth factor receptor c-terminal 
tail. Molecular biology of the cell 10, 525-536. 
Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., 
Tsien, J. Z., Schultz, P. G., Rose, M. D., et al. (2000). A chemical switch for inhibitor-sensitive 
alleles of any protein kinase. Nature 407, 395-401. 
Blair, J. A., Rauh, D., Kung, C., Yun, C. H., Fan, Q. W., Rode, H., Zhang, C., Eck, M. J., Weiss, W. 
A., and Shokat, K. M. (2007). Structure-guided development of affinity probes for tyrosine kinases 
using chemical genetics. Nat Chem Biol 3, 229-238. 
Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994). Jak-STAT pathways and transcriptional 
activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421. 
Doucette, T. A., Kong, L. Y., Yang, Y., Ferguson, S. D., Yang, J., Wei, J., Qiao, W., Fuller, G. N., 
Bhat, K. P., Aldape, K., et al. (2012). Signal transducer and activator of transcription 3 promotes 
angiogenesis and drives malignant progression in glioma. Neuro-oncology. 
Dubuc, A. M., Remke, M., Korshunov, A., Northcott, P. A., Zhan, S. H., Mendez-Lago, M., Kool, M., 
Jones, D. T., Unterberger, A., Morrissy, A. S., et al. (2013). Aberrant patterns of H3K4 and H3K27 
histone lysine methylation occur across subgroups in medulloblastoma. Acta neuropathologica 
125, 373-384. 
Fan, Q. W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., and Weiss, 
W. A. (2007). A Dual Phosphoinositide-3-Kinase {alpha}/mTOR Inhibitor Cooperates with 
Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant Glioma. Cancer research 67, 
7960-7965. 
Fan, Q. W., and Weiss, W. A. (2004). RNA interference against a glioma-derived allele of EGFR 
induces blockade at G(2)M. Oncogene. 
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., and Aldape, 
K. (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma 
multiforme patients. Clinical cancer research : an official journal of the American Association for 
Cancer Research 11, 1462-1466. 
Huang, H. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X. D., Huang, C. M., Gill, G. N., 
Wiley, H. S., and Cavenee, W. K. (1997). The enhanced tumorigenic activity of a mutant 
epidermal growth factor receptor common in human cancers is mediated by threshold levels of 
constitutive tyrosine phosphorylation and unattenuated signaling. The Journal of biological 
chemistry 272, 2927-2935. 
Inda, M. M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W., Vandenberg, S., Brennan, C., Johns, T. 
G., Bachoo, R., Hadwiger, P., et al. (2010). Tumor heterogeneity is an active process maintained 
by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24, 1731-1745. 
Johns, T. G., Perera, R. M., Vernes, S. C., Vitali, A. A., Cao, D. X., Cavenee, W. K., Scott, A. M., and 
Furnari, F. B. (2007). The efficacy of epidermal growth factor receptor-specific antibodies against 
glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin 
Cancer Res 13, 1911-1925. 
 23 
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., and 
Kuriyan, J. (2009). Mechanism for activation of the EGF receptor catalytic domain by the 
juxtamembrane segment. Cell 137, 1293-1307. 
Lo, H. W., Cao, X., Zhu, H., and Ali-Osman, F. (2010). Cyclooxygenase-2 is a novel transcriptional 
target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Molecular cancer 
research : MCR 8, 232-245. 
Luwor, R. B., Zhu, H. J., Walker, F., Vitali, A. A., Perera, R. M., Burgess, A. W., Scott, A. M., and 
Johns, T. G. (2004). The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes 
cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23, 6095-6104. 
McBeth, L. R., St-Pierre, N. R., Shoemaker, D. E., and Weiss, W. P. (2013). Effects of transient 
changes in silage dry matter concentration on lactating dairy cows. Journal of dairy science. 
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., 
Yoshimoto, K., Huang, J. H., Chute, D. J., et al. (2005). Molecular determinants of the response of 
glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024. 
Nishikawa, R., Sugiyama, T., Narita, Y., Furnari, F., Cavenee, W. K., and Matsutani, M. (2004). 
Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in 
glioblastoma. Brain tumor pathology 21, 53-56. 
Pandita, A., Aldape, K. D., Zadeh, G., Guha, A., and James, C. D. (2004). Contrasting in vivo and in 
vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes, chromosomes & 
cancer 39, 29-36. 
Parsons, J. B., Kukula, M., Jackson, P., Pulse, M., Simecka, J. W., Valtierra, D., Weiss, W. J., 
Kaplan, N., and Rock, C. O. (2013). Perturbation of Staphylococcus aureus Gene Expression by 
the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252. Antimicrobial agents and 
chemotherapy. 
Ramnarain, D. B., Park, S., Lee, D. Y., Hatanpaa, K. J., Scoggin, S. O., Otu, H., Libermann, T. A., 
Raisanen, J. M., Ashfaq, R., Wong, E. T., et al. (2006). Differential gene expression analysis 
reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma 
cells. Cancer Res 66, 867-874. 
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., 
Sathornsumetee, S., Herndon, J. E., 2nd, Dowell, J. M., McLendon, R. E., et al. (2006). Phase 1 
trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical cancer research : 
an official journal of the American Association for Cancer Research 12, 860-868. 
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., 
Gilbert, M. R., Herndon, J. E., 2nd, McLendon, R. E., Mitchell, D. A., et al. (2010). Immunologic 
escape after prolonged progression-free survival with epidermal growth factor receptor variant III 
peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28, 4722-4729. 
Shao, H., Cheng, H. Y., Cook, R. G., and Tweardy, D. J. (2003). Identification and characterization of 
signal transducer and activator of transcription 3 recruitment sites within the epidermal growth 
factor receptor. Cancer Res 63, 3923-3930. 
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., 
Hirano, H., Kuratsu, J., et al. (2003). Prognostic value of epidermal growth factor receptor in 
patients with glioblastoma multiforme. Cancer Res 63, 6962-6970. 
Sugawa, N., Ekstrand, A. J., James, C. D., and Collins, V. P. (1990). Identical splicing of aberrant 
epidermal growth factor receptor transcripts from amplified rearranged genes in human 
glioblastomas. Proceedings of the National Academy of Sciences of the United States of America 
87, 8602-8606. 
Thiel, K. W., and Carpenter, G. (2007). Epidermal growth factor receptor juxtamembrane region 
regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci U S A 104, 19238-19243. 
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., 
Schackert, G., Simon, M., Tonn, J. C., et al. (2009). Molecular predictors of progression-free and 
 24 
overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of 
the German Glioma Network. J Clin Oncol 27, 5743-5750. 
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., and 
Vogelstein, B. (1992). Structural alterations of the epidermal growth factor receptor gene in 
human gliomas. Proceedings of the National Academy of Sciences of the United States of 
America 89, 2965-2969. 
 
 
 
 
 
FIGURE LEGENDS 
Figure 1. Detection of EGFR and EGFRvIII in primary human glioblastoma. (A) Graphical analysis of 
immunohistochemical data from Table S1. (B-C)  Immunohistochemical staining of a primary human 
GBM with EGFR-specific (top panel) or EGFRvIII-specific antibody (bottom panel) on consecutive 
sections (brown, diaminobenzidine; light blue, nuclear counterstain with hemalum). Black scale bar 
corresponds to 50 m.  (C) Immunofluorescence double-staining of primary GBM tissue sections 
using EGFR-specific and EGFRvIII-specific antibodies.  Cells double-positive for both EGFR-WT and 
EGFRvIII are indicated by arrows. An enlarged image of region marked with a white square (upper 
left panel in (C)) is shown on the right side. Lower panels demonstrate EGFR-WT/EGFRvIII-positive 
tumor cells in two additional distinct tumors; green fluorescence, EGFR-WT; red fluorescence, 
EGFRvIII; blue fluorescence, nuclei (4',6-diamidino-2-phenylindole). White scale bar corresponds to 
10 m. Staining in A used pan EGFR antibody (Ventana 790-2988, clone 3C6) and EGFRvIII 
antibody (Duke University, L8A4).  Staining in B and C used EGFR antibody (Dako DAK-H1-WT) and 
EGFRvIII antibody (Celldex polyclonal rabbit antiserum 6549).  See also Figure S1 and Table S1.   
 
Figure 2. Co-expression of EGFR and EGFRvIII enhances malignancy. (A, B) Anchorage-
independent growth of LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII 
cells was measured by colony formation in soft agar, in the presence or absence of EGF (50 ng/ml). 
(A) Representative colonies were photographed after 3 weeks. Scale bar corresponds to 50 m.  (B) 
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The number of colonies on 6-well plates in triplicate, normalized to parental cells without EGF, was 
quantified after 3 weeks. Data are presented as mean  SE obtained from three 6-well plates. **, p < 
0.05, ***, p < 0.0001. (C, D) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, and LN-
229:EGFR/EGFRvIII cells (106) were injected subcutaneously and separately in BALB/c nu/nu 
animals, 5 mice/group. (C) Representative tumors after 6 weeks. Scale bar corresponds to 10 mm.  
(D) Each point represents mean tumor volume  SE obtained from five mice. See also Figure S2.  
 
 
Figure 3. Co-expression of EGFR and EGFRvIII is associated with phosphorylation of STAT proteins. 
(A) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-
staved for 24 hr then treated with or without EGF (50 ng/ml) for 15 min prior to harvest, lysis, and 
analysis by immunoblot using antisera indicated (left panels). This same panel of cells (106) was 
injected subcutaneously in BALB/c nu/nu mice, and animals were sacrificed after 6 weeks. Two 
representative tumors in each group were lysed, and analyzed by immunoblot (right panels). (B) 
Control (autopsy specimen) or human GBMs from the Brain Tumor Research Center at UCSF were 
lysed and analyzed by immunoblot with the antisera indicated.  EGFR and EGFRvIII status were pre-
confirmed by immunohistochemical staining.  Samples were lysed and immunoblotted. In EGFR 
immunoblot, the top band (arrow) has mobility of wild-type EGFR, whereas the lower band 
(arrowhead) has mobility of EGFRvIII. The intensity of p-STAT3, quantified by densitometry using 
Silver Fast Scanner and ImageJ software, is shown below each immunoblot as fold increase relative 
to normal brain, normalized to GAPDH (bottom panel). (C and D) Immunohistochemical staining of 
adjacent sections (left) and immunofluorescent costaining of primary glioblastoma tissue using EGFR, 
EGFRvIII, and p-STAT3 (Tyr705, mouse monoclonal antibody 3E2, Cell Signaling) specific antibodies 
(right).  Arrows indicate position of the nucleus and identify tumor cells positive for both EGFR (green) 
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and p-STAT3 (red); or for both EGFRvIII (green) and p-STAT3 (red). Black scale bar corresponds to 
100 m and white bar to 10 m. See also Figure S3.  
 
 
Figure 4. EGF treatment of LN-229:EGFR/EGFRvIII cells leads to prolonged phosphorylation of 
EGFR, EGFRvIII, and STAT3/5. (A) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-
229:EGFR/EGFRvIII cells were serum-starved for 24 hr then treated with EGF (50 ng/ml) for times 
shown, prior to harvest, lysis, and analysis by immunoblot using antisera indicated (Top panel). (B) 
Cells were grown in 10% FBS then treated with protein synthesis inhibitor cycloheximide (CHX, 50 
μg/ml) for times shown, prior to harvest, lysis, and analysis by immunoblot using antisera indicated 
(Top panel). EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead. (A, B) The 
intensity of each protein, quantified by densitometry using Silver Fast Scanner and ImageJ software, 
is shown below each immunoblot--as fold increase relative to untreated samples (EGF 0 hr or 
cycloheximide 0 hr) after normalization to GAPDH (Bottom panel). See also Figure S4. 
 
Figure 5. Unidirectional phosphorylation of EGFRvIII by EGFR correlates with proliferation and 
transformation. (A) Chemical genetic approach: as-allele-selective irreversible inhibitor 4TB did not 
affect EGFR or EGFRvIII, while as-alleles of these kinases (EGFRas3, EGFRvIIIas3) were inhibited. 
EGFRvIIIDY5 represents an allele of EGFRvIII with tyrosine mutated to phenylalanine at codons 992, 
1068, 1086, 1148, and 1173. (B) Immunoblot of NIH3T3 cells transduced with EGFR, EGFRvIII, 
EGFRas3, EGFRvIIIas3, EGFR/EGFRvIII, EGFRas3/EGFRvIII, EGFR/EGFRvIIIas3, or 
EGFR/EGFRvIIIDY5.  Cells were grown in 10% FBS and treated with or without indicated doses of 4TB 
for 24 hr. EGF (50 ng/ml) was added to cells 15 min before harvest, and lysates immunoblotted using 
antisera indicated. EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead. (C) 
NIH3T3 cells stably transduced with the indicated retroviral constructs were grown in 10% FBS and 
treated with or without 0.5 M of 4TB. Cell proliferation (WST-1 assay, top panel), flow cytometry 
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(middle panel), and focus formation analyses (bottom panel). Data are mean  SD of triplicate 
measurements. See also Figure S5. 
 
Figure 6. EGFRvIII serves as a substrate for EGFR. LN-229 cells stably transduced with retroviral 
constructs indicated were serum-starved for 24 hr then treated with or without EGF (50 ng/ml) for 15 
min prior to harvest.  Lysates were immunoblotted using antisera indicated. (A) Cartoon of receiver 
impaired (I682Q) or activator impaired (V924R) mutations.  Bracketed numbers correspond to those 
in (B). (B) LN-229 cells co-transduced with EGFRI682Q/EGFRvIIIV924R or with EGFRV92R/EGFRvIIII682Q. 
EGFR is indicated by arrow. EGFRvIII is indicated by arrowhead. (C) Cartoon of EGFR, EGFR kinase 
dead (D813N), EGFRvIII, EGFRvIII kinase dead (D813N) and combinations.  Bracketed numbers 
correspond to those in (D). (D) LN-229 cells co-transduced with EGFRWT, EGFRD813N, EGFRvIII, 
EGFRvIIID813N or combinations. EGFR is indicated by arrow. EGFRvIII is indicated by arrowhead. See 
also Figure S6. 
 
Figure 7. EGFR and EGFRvIII cooperate to active STAT in the nucleus. (A) LN-229:parent, LN-
229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr then 
treated with EGF (50 ng/ml) for times shown. Samples were harvested, subject to subcellular 
fractionation to obtain membrane (M), cytoplasmic (C), and nuclear (N) extracts, and analyzed by 
immunoblot using antisera indicated. EGFR is indicated by arrow, whereas EGFRvIII is indicated by 
arrowhead. (B) LN-229:EGFRvIII, LN-229:EGFRvIIIdNLS, LN-229:EGFR/EGFRvIIIdNLS, or LN-
229:EGFR/EGFRvIII were serum-starved for 24 hr then treated with EGF (50 ng/ml) for 0 and 15 min, 
whole cell lysates or nuclear extracts were analyzed by immunoblot using antisera indicated. (C) 
LN229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-
starved for 24 hr then treated with EGF (50 ng/ml) for 0 and 15 min, and fractionated to obtain nuclear 
extracts.  Nuclear STAT3 was immunoprecipitated using a mouse monoclonal STAT3 antibody, and 
immunoprecipitates analyzed by immunoblot to detect EGFR and EGFRvIII (using a rabbit polyclonal 
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EGFR antibody, which recognizes both EGFR and EGFRvIII). Efficacy of subcellular fractionation in 
A, B, and C is indicated by membrane and cytoplasmic marker protein β-Tubulin, cytoplasmic marker 
protein GAPDH, and nuclear marker protein Lamin B1. See also Figure S7. 
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Figure S1, related to Figure 1.  Expression and characterization of EGFR and 
EGFRvIII antibodies. 
 
(A, B) Human glioblastoma section stained with hematoxylin and eosin (H&E). 
 
(C, D) Human glioblastoma section stained with antibody (L8A4), which is specific 
to EGFRvIII. 
 
(E, F) Human glioblastoma section stained with pan EGFR antibody (3C6), which 
recognizes the N-terminus of both EGFR-WT and EGFRvIII.  
 
(B, D, F) Enlarged image of regions marked with black squares in (A, C, E). Scale 
bar corresponds to 500 m in (A, C, E) and 50 m in (B, D, F). 
 
(G) EGFR antibody (clone DAK-H1-WT, Dako) reacts with N-terminus of the 
extracellular domain of wild-type EGFR and does not detect EGFRvIII. The 
EGFRvIII antibody (polyclonal rabbit antiserum 6549, Celldex) recognizes the exon 
1/exon 8 junction fragment specific to EGFRvIII.  Immunofluorescence double 
staining detecting EGFR in LN-229:EGFR and LN-229:EGFR/EGFRvIII cells by 
anti-EGFR antibody. EGFRvIII was detected in LN-229:EGFRvIII and LN-
229:EGFR/EGFRvIII cells by anti-EGFRvIII antibody. Scale bar corresponds to 5 
m.   
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Patient 
No 
EGFR/ 
EGFRvIII 
Ab (3C6) 
 
EGFRvIII 
Ab (L8A4) 
EGFR/ 
EGFRvIII 
(Status) 
 
Patient 
No 
EGFR/ 
EGFRvIII 
Ab (3C6) 
 
EGFRvIII 
Ab (L8A4) 
EGFR/ 
EGFRvIII 
(Status) 
1 0 0 − 30 0 0 − 
2 3 0 − 31 3 3 + 
3 3 0 − 32 3 3 + 
4 3 0 − 33 3 1 + 
5 0 0 − 34 1 0 − 
6 3 0 − 35 3 0 − 
7 3 0 − 36 3 0 − 
8 1 0 − 37 2 0 − 
9 2 0 − 38 3 0 − 
10 3 2 + 39 2 2 + 
11 3 0 − 40 3 3 + 
12 2 0 − 41 0 0 − 
13 1 3 + 42 2 0 − 
14 3 1 + 43 3 0 − 
15 3 0 − 44 2 0 − 
16 0 0 − 45 3 0 − 
17 3 1 + 46 3 0 − 
18 0 0 − 47 3 2 + 
19 3 0 − 48 0 0 − 
20 3 0 − 49 1 0 − 
21 3 0 − 50 2 0 − 
22 1 0 − 51 0 0 − 
23 0 0 − 52 2 0 − 
24 2 0 − 53 2 0 − 
25 1 0 − 54 1 0 − 
26 0 0 − 55 2 0 − 
27 3 0 − 56 3 3 + 
28 3 0 − 57 3 0 − 
29 3 0 − 58 1 0 − 
Sequential human primary glioblastoma tissue sections were stained with pan EGFR antibody 
(3C6), which recognizes the N-terminus of both EGFR and EGFRvIII and EGFRvIII antibody 
(L8A4), which is specific to EGFRvIII. Immunohistochemical evaluation of EGFR and 
EGFRvIII, scored semi-quantitatively by UCSF neuropathologists as standard-of-care, was 
extracted from the clinical pathology report. IHC Score: 0 = No positive staining; 1 = 1-25% 
immunoreactivity of cells; 2 = 26-75% immunoreactivity; 3 = >75% immunoreactivity; (–) = 
Tumors were EGFR negative/EGFRvIII negative staining or EGFR positive/EGFRvIII negative 
staining; (+) = Tumors were EGFR positive/EGFRvIII positive staining.  
 
 
Table S1, related to Figure 1. EGFR, EGFRvIII, and EGFR/EGFRvIII status in 
human clinical glioma specimens 
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Figure S2, related to Figure 2. Co-expression of EGFR and EGFRvIII increased 
colony formation in soft agar.  Mouse fibroblast NIH3T3, human glioma cell lines 
U87MG, were all stably transduced with the indicated retroviral constructs.  
Anchorage-independent growth was measured by colony formation in soft agar, in 
the presence or absence of EGF (50 ng/ml) for 3 weeks.  
 
(A) Representative colonies were photographed after 3 weeks. Scale bar 
corresponds to 50 m.  
 
(B) Data are presented as mean  SE obtained from three 6-well plates. **, p < 
0.05, ***, p < 0.0001. 
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Figure S3, related to Figure 3. EGFR phosphorylation of EGFRvIII promotes 
phosphorylation of STAT protein in rodent fibroblasts, human glioblastoma cell 
lines, and primary human glioblastoma tumors. 
 
(A) Cells were serum-starved for 24 hr treated with or without EGF (50 ng/ml) for 15 min, 
then harvested, lysed, and analyzed by immunoblot using antisera indicated. Arrow 
denotes EGFR, whereas arrowhead denotes EGFRvIII.  
 
(B-D) The intensity of each p-EGFRY1173, p-EGFRvIIIY1173, p-STAT3, and p-STAT5 protein, 
quantified by densitometry using Silver Fast Scanner and ImageJ software, is shown after 
normalization to GAPDH. Data are presented as mean  SE obtained from three 
independent experiments. NS, not significant, **, p < 0.05. 
 
(E) Abundance of EGFR, EGFRvIII, and p-STAT3 in primary human glioblastoma tumors. 
Control (autopsy specimen) or human glioblastomas from the Brain Tumor Research 
Center at UCSF were lysed and immunoblotted. In EGFR immunoblot (top panel), upper 
band, arrow, has mobility of wild-type EGFR, whereas lower band, arrowhead, has 
mobility of EGFRvIII. The intensity of each protein was quantified by densitometry using 
Silver Fast Scanner and ImageJ software.  Bar graph quantifies fold increase relative to 
control (autopsy specimen) after normalizing to β-Tubulin (Bottom panel). 
 
(F) Abundance of p-STAT3 in human glioblastoma tumors. The intensity of each protein 
(same samples used in Fig. 3B) was quantified by densitometry using Silver Fast Scanner 
and ImageJ software. Bar graph quantifies fold increase relative to control (autopsy 
specimen) after normalizing to STAT3. 
 
(G) Abundance of p-STAT3 in human glioma tumors. The intensity of each protein (same 
sample used in (E) was quantified by densitometry using Silver Fast Scanner and ImageJ 
software. Bar graph quantifies fold increase relative to control (autopsy specimen) after 
normalizing to STAT3. 
(H) Immunofluorescence staining of EGFRvIII in primary glioblastoma tumors. The 
EGFRvIII antibody (polyclonal rabbit antiserum 6549, Celldex) recognizes the exon 1/exon 
8 junction fragment that is specific to EGFRvIII, and does not detect EGFR.  Arrows 
indicate position of the nucleus. Scale bar corresponds to 5 m. 
(I) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells 
were serum-starved for 24 hr then treated with or without EGF (50 ng/ml) for 15 min, then 
harvested, lysed, and analyzed by immunoblot with five different site-specific anti-EGFR 
antibodies. EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead. 
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Figure S4, related to Figure 4. The expression of 33 distinct genes was 
significantly altered in EGFR/EGFRvIII coamplified (n=77) versus EGFR-
amplified (n=116) samples (p< 0.05).  
 
(A) Heatmap of the differentially expressed genes with EGFR/EGFRvIII 
coamplified and EGFR-amplified samples clustered separately.   
 
(B) Network analysis generated through the use of ingenuity pathway analysis 
(www.ingenuity.com).   EGFR/EGFRvIII signaling intervenes through this network 
via PKC, calcium and PLC (blue circles).  Increases (red) or decreases (green) in 
gene expression are indicated with respect to EGFR/EGFRvIII versus EGFR 
amplification status. 
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Figure S5, related to Figure 5. Selective knockdown of EGFRvIII decreases 
proliferation, associated with decreased levels of both p-STAT3 and p-STAT5 in 
LN-229:EGFR/EGFRvIII cells. LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, and 
LN-229:EGFR/EGFRvIII cells were treated as indicated. Cells in A were grown in 
DMEM containing 10% FBS without EGF stimulation, representing steady state 
conditions. Cells in B and C were grown in DMEM containing 0.5% FBS. EGF (50 
ng/ml) was added 15 min before harvest.   
 
(A) Specificity of EGFRvIII siRNA, proliferation analysis. LN-229:parent, LN-229:EGFR, 
LN-229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells were transfected with either 
control siRNA alone, control siRNA plus EGFR inhibitor erlotinib (3 μM), EGFRvIII 
siRNA alone or EGFRvIII siRNA plus erlotinib (3 μM) for 3 days. Cell proliferation was 
measured by WST-1 and analyzed by spectrophotometric analysis (Absorbance = 450 
nm). Data shown are means ± SE for triplicate measurements. NS, not significant. **, p 
< 0.05. ***, p < 0.001. 
  
(B) Specificity of EGFRvIII siRNA, immunoblot analysis. EGF (50 ng/ml) was added 15 
min before harvest to cells indicated.  An aliquot of cells was analyzed by immunoblot 
with antisera indicated. Arrow indicates mobility of wild-type EGFR, whereas arrowhead 
indicates mobility of EGFRvIII. 
 
(C) Combination therapy using EGFRvIII siRNA with the EGFR inhibitor erlotinib. EGF 
(50 ng/ml) was added 15 min before harvest to cells indicated.  Lysates were 
immunoblotted using antisera indicated. Arrow indicates mobility of wild-type EGFR, 
whereas arrowhead indicates mobility of EGFRvIII. 
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Figure S6, related to Figure 6. EGFR and EGFRvIII signal by a 
heterodimerization-independent mechanism.  
 
(A) Cartoon of receiver-impaired (I682Q) or activator-impaired (V924R) mutations in 
EGFR.   
 
(B-D) Receiver-impaired EGFRI682Q and activator-impaired EGFRV924R were 
transduced alone or in combination, in human glioma line LN-229 or mouse fibroblast 
NIH3T3 cells. EGF was added 15 min before harvest, and lysates were immunoblotted 
using antisera indicated.  
 
(E) Proposed interactions between receiver-impaired EGFRI682Q and activator-impaired 
EGFRV924R.  
 
(F) Cartoon of receiver impaired (I682Q) or activator impaired (V924R) mutations in 
EGFRvIII.  
 
(G) Characterization of EGFRvIIII682Q and EGFRvIIIV924R in glioma cells and fibroblasts. 
Receiver-impaired EGFRvIIII682Q and activator-impaired EGFRvIIIV924R alleles of 
EGFRvIII were transduced into human glioma line LN-229 or mouse NIH3T3 cells. 
EGF (50 ng/ml) was added to cells 15 min before harvest, and lysates were 
immunoblotted using antisera indicated.  
 
(H) The same samples as in Figure 6B were immunoblotted using antisera indicated.  
 
(I-J) NIH3T3:parent, NIH3T3:EGFR, NIH3T3:EGFRvIII, and NIH3T3:EGFR/EGFRvIII 
cells treated with or without EGF (50 ng/ml) for 15 min were harvested. (I) Whole cell 
lysates (input). (J) Western blot from IP samples. Immunoprecipitation (IP) was 
performed using anti-EGFR mouse monoclonal antibody (IP specific, Cell Signaling), 
and then followed by Western blot analysis probing for EGFR (rabbit antibody, Santa 
Cruz Biotechnology). EGFR is indicated by arrow, whereas EGFRvIII is indicated by 
arrowhead. 
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Figure S7, related to Figure 7. STAT3 inhibitors and EGFR inhibitors cooperate 
to block proliferation and increase apoptosis in human glioma cell lines.    LN-
229:parent, LN-229:EGFR, LN-229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells 
were treated with DMSO, STAT3 inhibitor (Stattic 3 μM), with EGFR inhibitor 
(erlotinib 3 μM), or with both agents. Cells were grown in DMEM containing 10% FBS 
without stimulation. 
 
(A) Cell proliferation were measured by WST-1 and analyzed by spectrophotometric 
analysis (Absorbance = 450 nm). Data shown are means ± SE for triplicate 
measurements.  
 
(B) Apoptosis was measured by flow cytometry for the apoptotic marker annexin V. 
Percentage of apoptotic cells was determined using FlowJo software. Data shown 
are means ± SE for triplicate measurements.  
 
(C) An aliquot of cells was analyzed by immunoblot with antisera indicated.    
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 Supplemental Experimental Procedures 
 
Immunoprecipitation (IP) 
For immunoprecipitation, NIH3T3:parent, NIH3T3:EGFR, NIH3T3:EGFRvIII, and 
NIH3T3:EGFR/vIII cells treated with or without EGF (50 ng/ml, 15 min) were 
harvested. Whole cell lysates (300 g total protein) were incubated with 1 g anti-
EGFR mouse monoclonal antibody (IP specific, Cell Signaling) at 4
0
C overnight with 
gentle agitation. Following addition of 20 l protein G-agarose and incubation for 1 hr 
at 4
0
C, the immunocomplexes were pelleted, washed for multiple cycles at 4
0
C, and 
then subjected to SDS-PAGE and Western blotting analysis probing for EGFR (rabbit 
antibody, Santa Cruz Biotechnology) and p-EGFR (Tyr1173) (rabbit antibody, Santa 
Cruz Biotechnology). 
 
siRNA transfection 
Control siRNA and synthetic EGFRvIII siRNA were purchased from (Dharmacon). 
Cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen) as directed 
by the manufacturer. 
 
Analysis of array CGH and gene expression 
Normalized level 2 Array CGH (Agilent Human Genome CGH Microarray 244A) and 
Expression Array (Affymetrix Human Genome U133 Plus 2.0 Array) data were 
downloaded from the TCGA repository.  Samples with EGFR amplification (defined as 
the mean of all aCGH probes directed to the EGFR locus >1) and expression array 
data were identified. EGFRvIII status was assessed by comparing the log2 ratio of the 
 19 
aCGH probe in the EGFRvIII deleted region to the mean of the remaining probes 
mapping 3’ to intron 7.  Of 193 samples with EGFR amplification, 77 were defined as 
EGFRVIII-positive by having a difference greater than the mean.   Differential gene 
expression between the EGFRvIII and EGFR-amplified samples was analyzed using 
an empirical Bayes approach.  Significant genes were identified with an adjusted p-
value below 0.05.  Statistical analysis was carried out in R using the eBayes function 
within the Limma package. 
  
 
 
 
 
 
